There is a lack of definitive evidence for the optimal therapeutic strategy in patients with concurrent CKD and CAD presenting with ACS, highlighting the need for further research.
ACS management in CKD-CAD lacks definitive guidance; leaves open optimal strategies pending dedicated RCTs.
Patients with CKD and CAD represent a challenging population, more randomized controlled trials and meta-analyses are needed to better define the best therapeutic strategy during an ACS episode.
No takes yet. Share an insight, caveat, or question.
Mauro et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: